Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | NAMPT | P43490 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 3/20 | 0.35 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10109057 | 0.87 | KMT2A (0.41) | ALDH1A1KMT2ANAMPTTDP1HTT | |
| SCHEMBL16219492 | 0.83 | KMT2A (0.44) | KMT2ATDP1HTTPOLB | |
| SCHEMBL16219381 | 0.83 | KMT2A (0.44) | KMT2ANAMPTTDP1HTTPOLB | |
| SCHEMBL19975948 | 0.80 | ALDH1A1 (0.48) | ALDH1A1SMN1; SMN2KMT2ALMNATDP1 | |
| SCHEMBL12139785 | 0.79 | KMT2A (0.47) | KMT2ATDP1HTTPOLB | |
| SCHEMBL20328072 | 0.78 | LMNA (0.55) | ALDH1A1SMN1; SMN2KMT2ALMNAPOLB | |
| SCHEMBL10102873 | 0.77 | SMN1; SMN2 (0.39) | SMN1; SMN2KMT2ALMNAPOLB | |
| SCHEMBL13347327 | 0.75 | KMT2A (0.73) | SMN1; SMN2KMT2ATDP1HTTPOLB | |
| SCHEMBL18713107 | 0.75 | KDM4E (0.46) | ALDH1A1SMN1; SMN2KMT2ATDP1HTT | |
| SCHEMBL10245087 | 0.74 | TDP1 (0.54) | KMT2ANAMPTTDP1HTTPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8841324-B2 | Heterocyclic compounds as autotaxin inhibitors | MERCK PATENT GMBH (DE) | 2014-09-23 | — | — | US | disclosed |
| US-20120015959-A1 | HETEROCYCLIC COMPOUNDS AS AUTOTAXIN INHIBITORS | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2012-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120015959-A1 | HETEROCYCLIC COMPOUNDS AS AUTOTAXIN INHIBITORS | ENPP2, HAX1, MTX1 | ALDH1A1 4564/4885SMN1; SMN2 4505/4885KMT2A 1968/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.